{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"27","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"A Bayesian design intended to simultaneously monitor efficacy and toxicity will be used.\n\nTRM: Treatment Related Mortality","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\npravastatin sodium: Given PO\n\nidarubicin: Given IV\n\ncytarabine: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"28 days","title":"Number of Participants With TRM.","type":"PRIMARY","unitOfMeasure":"participants"}